Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

  1. Girard, N.
  2. Bar, J.
  3. Garrido, P.
  4. Garassino, M.C.
  5. McDonald, F.
  6. Mornex, F.
  7. Filippi, A.R.
  8. Smit, H.J.M.
  9. Peters, S.
  10. Field, J.K.
  11. Christoph, D.C.
  12. Sibille, A.
  13. Fietkau, R.
  14. Haakensen, V.D.
  15. Chouaid, C.
  16. Markman, B.
  17. Hiltermann, T.J.N.
  18. Taus, A.
  19. Sawyer, W.
  20. Allen, A.
  21. Chander, P.
  22. Licour, M.
  23. Solomon, B.
Revue:
Journal of Thoracic Oncology

ISSN: 1556-1380,  1556-0864

Année de publication: 2023

Volumen: 18

Número: 2

Pages: 181-193

Type: Article

DOI: 10.1016/J.JTHO.2022.10.003 GOOGLE SCHOLAR lock_openAccès ouvert editor

Objectifs de Développement Durable

La source de données: Scopus